In February 2011, Crucell NV was acquired by Johnson & Johnson, and now is a subsidiary of that firm. Crucell N.V., a biopharmaceutical company, discovers, develops, manufactures, markets, and distributes vaccines, proteins, and antibodies against various infectious diseases in the paediatric, travel and endemic, and respiratory fields. The company offers Quinvaxem, a liquid vaccine to protect against various childhood diseases; Hepavax-Gene, a recombinant hepatitis B vaccine; Epaxal Junior, a low dosage, aluminum-free hepatitis A vaccine; Vivotif, an oral typhoid vaccine; Dukoral, an oral vaccine against cholera; and Inflexal V, a Virosomal adjuvanted influenza vaccine. It also develops CR8020, an anti-influenza antibody for neutralizing group 2 influenza A viruses; and licenses its technologies to the biopharmaceutical industry. The company offers vaccines against various infectious diseases, such as influenza, hepatitis A, hepatitis B, and typhoid fever. It provides its products in the Netherlands and internationally. The company has strategic agreements with DSM Biologics, Novartis, sanofi pasteur, and Wyeth. Crucell N.V. was formerly known as IntroGene B.V. and changed its name to Crucell N.V. in 2000. The company was founded in 1993 and is based in Leiden, the Netherlands with additional offices in China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, the United Kingdom, the United States, and Vietnam. As of February 22, 2011, Crucell N.V. operates as a subsidiary of Cilag Holding AG
